The PennZone

~ Carisma Therapeutics Inc. (Nasdaq: CARM) has announced the addition of Sohanya Cheng, MBA to their Board of Directors, effective October 31, 2024. The clinical-stage biopharmaceutical company is focused on developing immunotherapies and is excited to have Ms. Cheng join their team.

According to Sanford Zweifach, Chair of the Carisma Board, Ms. Cheng's extensive experience in oncology and her skills in leadership, strategic planning, and commercialization will be valuable assets as the company continues to advance its portfolio and strengthen its foundation.

In addition to Ms. Cheng's appointment, Michael Torok has informed the Board of his intention to step down as a member on October 31, 2024 due to other professional commitments. The Board is grateful for Mr. Torok's service and wishes him well in his future endeavors.

More on The PennZone

• 10 Warning Signs a Roof May Need Repair Before Major Damage Occurs
• $1B Target by 2027 Amid eSIM, Global Roaming Expansion; $57.6M Q1 Revenue and Market Uplisting, Advancing Toward IQSTEL, Inc. (Stock Symbol: IQST)
• LIB TH-50/TH-80 Benchtop Environmental Chamber Drives Global Demand
• Marc Soucy's Newest Music Series Approaches Its One Year Mark
• Fairmint Releases Whitepaper for Open Captable Protocol (OCP) to Advance On-Chain Equity Securities

Ms. Cheng expressed her enthusiasm for joining Carisma's Board and working with the management team as they strive to deliver innovative immunotherapies to patients facing serious diseases. She looks forward to sharing her insights and supporting the company's strategic goals as it solidifies its position as a leader in engineered macrophages within oncology and beyond.

Carisma Therapeutics Inc. is dedicated to making a positive impact in the field of immunotherapy and is confident that Ms. Cheng's expertise will contribute greatly towards achieving this goal.

---

Show All News | Report Violation